In earlier studies, we demonstrated the positive effect of gene-modified UCB-MCs producing recombinant vascular endothelial growth factor (VEGF) on the symptomatic outcome and life-span of transgenic ALS mice [38]. This evidence concerns the gene VEGFA and amyotrophic lateral sclerosis.